Depo-Provera Limitations and Disadvantages

Introduction to Depo-Provera's Poor Continuation Rates

The Centers for Disease Control and Prevention recommends that Depo-Provera has a poor continuation rate of only 56% at one year, driven by menstrual irregularities, weight gain concerns, and bone density loss warnings, according to the CDC 1, 2.
The American College of Obstetricians and Gynecologists notes that Depo-Provera has the lowest continuation rate among highly effective reversible contraceptive methods, with nearly half of women discontinuing use within the first year 1, 2, 3.

The CDC reports that Depo-Provera has a 56% continuation rate at one year, compared to 78% for the Copper IUD, 80% for the Hormonal IUD, 84% for the Implant, and 67% for combined oral contraceptives 1, 2, 3.
The American College of Rheumatology conditionally recommends IUDs or subdermal implants as first-line contraceptives due to their <1% failure rates, with Depo-Provera as an alternative when other methods are not feasible or preferred 4.

The American College of Obstetricians and Gynecologists recommends bone density evaluation when long-term use of Depo-Provera is needed, due to progressive bone mineral density loss 4.
The FDA black box warning states that Depo-Provera should not be used for more than 2 years unless other methods are inadequate, due to bone mineral density loss 4.
Weight gain is a common concern with Depo-Provera, with studies showing that 21% of adolescents experience early weight gain, and these "early gainers" continue gaining weight over 18 months 4.

Depo-Provera has an excellent efficacy rate of 0.2% perfect use failure rate, according to the CDC 1, 2, 3.
Depo-Provera has an estrogen-free formulation, making it suitable for women with thromboembolism history, migraine with aura, or cardiovascular disease 4, 5.

The American College of Obstetricians and Gynecologists recommends that pre-injection counseling about menstrual changes significantly improves continuation rates 4.